• Explore /
  • Poster
  • / Phase I study of LZM005, a HER2 antibody, as monotherapy or in combination with trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer.

Phase I study of LZM005, a HER2 antibody, as monotherapy or in combination with trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer.

Abstract Video & Slides Poster

Authors

null

Cong Xue

Department of Medical Oncology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China

Cong Xue , Herui Yao , Ying Lin , Xin An , Meiting Chen , Yugang Dong , Su Li , Yanxia Shi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

HER2-Positive

Clinical Trial Registration Number

CTR20191921

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 1042)

DOI

10.1200/JCO.2021.39.15_suppl.1042

Abstract #

1042

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Nehal J. Lakhani

First Author: Stephen K. L. Chia

Poster

2016 ASCO Annual Meeting

Phase I study of alpelisib and T-DM1 in trastuzumab-refractory HER2-positive metastatic breast cancer.

Phase I study of alpelisib and T-DM1 in trastuzumab-refractory HER2-positive metastatic breast cancer.

First Author: Sarika Jain

First Author: Payal Deepak Shah